Read article 'A word with CERN’s next Director-General'
A word with CERN’s next Director-General
Mark Thomson, CERN's Director General designate for 2025, talks to the Courier about the future of particle physics.
Thank you for registering
If you'd like to change your details at any time, please visit My account
Read article 'A word with CERN’s next Director-General'
Mark Thomson, CERN's Director General designate for 2025, talks to the Courier about the future of particle physics.
Read article 'CLOUD explains Amazon aerosols'
The CLOUD collaboration at CERN has revealed a new source of atmospheric aerosol particles that could help scientists to refine climate models.
Read article 'The new hackerpreneur'
Hackathons can kick-start your career, says hacker and entrepreneur Jiannan Zhang.
Read article 'Unprecedented progress in energy-efficient RF'
Forty-five experts from industry and academia met in the magnificent city of Toledo for the second workshop on efficient RF sources.
Read article 'ICFA talks strategy and sustainability in Prague'
The 96th ICFA meeting heard extensive reports from the leading HEP laboratories and various world regions on their recent activities and plans.
Read article 'AI treatments for stroke survivors'
Data on strokes is plentiful but fragmented, making it difficult to exploit in data-driven treatment strategies.
Read article 'Inside pyramids, underneath glaciers'
Coordinated by editors Paola Scampoli and Akitaka Ariga, Cosmic Ray Muography provides an invaluable snapshot of a booming research area.
Read article 'Threshold moment for medical photon counting'
The seventh workshop on Medical Applications of Spectroscopic X-ray Detectors was held at CERN from in April.
Read article 'Acceleration, but not as we know it'
On-chip acceleration pioneers Robert Byer, Joel England, Peter Hommelhoff and Roy Shiloh report on progress to miniaturise accelerators from centimetres to microns.
Read article 'How to democratise radiation therapy'
Manjit Dosanjh and Steinar Stapnes tell the Courier about the need to disrupt the market for a technology that is indispensable when treating cancer.